FDAapproval84% confidence
CDER proposes to withdraw approval of TAVNEOS
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Hikma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Emergency Medicine · Epinephrine
- Sub-indication
- General
Related signal: Hikma's Epinephrine ANDA220562 Receives Abbreviated Approval from FDA